Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Spruce Biosciences Inc. | Tildacerfont - (CAHmelia-203) | Congenital Adrenal Hyperplasia (poor disease control) | Phase 2b | Trial Discontinued | Oral | Endocrinology |
| Spruce Biosciences Inc. | Tildacerfont with Cortibon- (TAMARIND) | Major depressive disorder (MDD) | Phase 2 | Ongoing | Oral | Psychiatric |
| Spruce Biosciences Inc. | Tildacerfont | Classic Congenital Adrenal Hyperplasia | Phase 2 | Ongoing | Oral | Genetic Disorder |
| Spruce Biosciences Inc. | Tildacerfont - (CAHptain-205) | Pediatric Classic Congenital Adrenal Hyperplasia | Phase 2 | Trial Discontinued | Oral | Genetic Disorder |
| Spruce Biosciences Inc. | Tildacerfont - (POWER) | Polycystic Ovary Syndrome | Phase 2 | Trial Completed | Oral | Women's Health |
| Spyre Therapeutics Inc. | Pegzilarginase (AEB1102) - (PEACE) | Arginase I deficiency | BLA Filing | Ongoing | Intravenous | Genetic Disorder |
| Spyre Therapeutics Inc. | SPY072 - (SKYWAY-RD, basket study) | Rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA) | Phase 2 | Ongoing | Intravenous | Immunology: Anti-TNF |
| Spyre Therapeutics Inc. | SPY001, SPY002, SPY003 - (SKYLINE) | Crohn's disease | Phase 2 | Ongoing | SPY001 oral SPY002 intravenous SPY003 subcutaneous | Gastroenterology |
